Weiner S, Zweibel S L, Gross J N
Montefiore Medical Center, Bronx, New York 10467-2401, USA.
Cardiol Rev. 1999 Mar-Apr;7(2):71-6. doi: 10.1097/00045415-199903000-00009.
Hypertrophic cardiomyopathy (HCM) is a complex disease that is sometimes difficult to control with medical therapy. Surgical treatment is highly effective but can be associated with significant morbidity and mortality. It has been suggested in uncontrolled studies that patients with obstructive HCM may improve symptomatically when treated with dual-chamber pacing. Several hypotheses have been suggested to explain this phenomenon, but the mechanism still remains unclear. Many recent randomized trials showed much less uniform effects on symptoms than previously reported. These results indicate the need for further comprehensive inquiry into the effects of pacing on HCM before it can be recommended for widespread use. The data on the benefit of pacing therapy in dilated cardiomyopathy are much more recent and limited. Initial optimistic reports have been only partially confirmed.
肥厚型心肌病（HCM）是一种复杂的疾病，有时药物治疗难以控制。手术治疗效果显著，但可能伴有较高的发病率和死亡率。在非对照研究中，有人提出梗阻性HCM患者接受双腔起搏治疗后症状可能会改善。人们提出了几种假说来解释这一现象，但机制仍不清楚。最近的几项随机试验表明，其对症状的影响远不如先前报道的那样一致。这些结果表明，在推荐起搏治疗广泛应用于HCM之前，有必要对其效果进行进一步全面研究。关于起搏治疗在扩张型心肌病中的益处的数据更新且有限。最初的乐观报告仅得到部分证实。
